SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Carlsson Jörgen) "

Sökning: WFRF:(Carlsson Jörgen)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Qvarnstrom, O. F., et al. (författare)
  • Effects of affinity on binding of HER2-targeting Affibody molecules: Model experiments in breast cancer spheroids
  • 2011
  • Ingår i: International Journal of Oncology. - : D.A. Spandidos. - 1019-6439 .- 1791-2423. ; 39:2, s. 353-359
  • Tidskriftsartikel (refereegranskat)abstract
    • Binding of a targeting agent in tumor tissue is influenced by many factors such as molecular weight, charge and affinity of the targeting agent and vascularization of the tumor. In this study, we analyzed tumor cell binding of three HER2-specific and radiolabeled Affibody molecules with different affinities. The Affibody molecules had affinities in the range of 0.12-3.8 nM. Cellular binding was analyzed, after 2 h of incubation, in tumor spheroids composed of BT474 breast cancer cells, which highly express HER2. Binding was, due to the binding-site barrier,limited to the outer 15 +/- 5 mu m rim of the spheroids, independent of affinity when the concentration of the substances was low. When the concentration was high, the binding site barrier was overcome and the binding occurred approximately 35 +/- 5 mu m into the spheroids for the two high affinity substances and 50 +/- 5 mu m for the low affinity substance. The lower affinity might allow for penetration into deeper regions due to less firm binding. We conclude that there is a binding site barrier within tumor spheroids which can be overcome by increased concentration of substance and modified by affinity.
  •  
2.
  • Ruge, Toralph, et al. (författare)
  • Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease : A CLARICOR trial sub-study
  • 2019
  • Ingår i: Atherosclerosis. - 0021-9150 .- 1879-1484. ; 284, s. 202-208
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND AND AIMS: Raised levels of serum endostatin, a biologically active fragment of collagen XVIII, have been observed in patients with ischemic heart disease but association with incident cardiovascular events in patients with stable coronary heart disease is uncertain.METHODS: The CLARICOR-trial is a randomized, placebo-controlled trial of stable coronary heart disease patients evaluating 14-day treatment with clarithromycin. The primary outcome was a composite of acute myocardial infarction, unstable angina pectoris, cerebrovascular disease or all-cause mortality. In the present sub-study using 10-year follow-up data, we investigated associations between serum endostatin at entry (randomization) and the composite outcome and its components during follow-up. The placebo group was used as discovery sample (1204 events, n = 1998) and the clarithromycin-treated group as replication sample (1220 events, n = 1979).RESULTS: In Cox regression models adjusting for cardiovascular risk factors, glomerular filtration rate, and current pharmacological treatment, higher serum endostatin was associated with an increased risk of the composite outcome in the discovery sample (hazard ratio per standard deviation increase 1.11, 95% CI 1.03-1.19, p = 0.004), but slightly weaker and not statistically significant in the replication sample (hazard ratio 1.06, 95% CI 1.00-1.14, p = 0.06). In contrast, strong and consistent associations were found between endostatin and cardiovascular and all-cause mortality in all multivariable models and sub-samples. Addition of endostatin to a model with established cardiovascular risk factors provided no substantial improvement of risk prediction (<1%).CONCLUSIONS: Raised levels of serum endostatin might be associated with cardiovascular events in patients with stable coronary heart disease. The clinical utility of endostatin measurements remains to be established.
  •  
3.
  • Watz, J., et al. (författare)
  • Wood addition in the hatchery and river environments affects post-release performance of overwintering brown trout
  • 2019
  • Ingår i: Freshwater Biology. - : Wiley-Blackwell. - 0046-5070. ; 64:1, s. 71-80
  • Tidskriftsartikel (refereegranskat)abstract
    • Habitat structural complexity affects the behaviour and physiology of individuals, and responses to the environment can be immediate or influence performance later in life through delayed effects. Here, we investigated how structural enrichment, both pre-release in the hatchery rearing environment and post-release in the wild, influenced winter growth and site fidelity of brown trout stocked into side channels of a regulated river. Experiencing structural enrichment in the rearing environment during 3 months in autumn had no pre-release effect on growth, but a delayed positive effect after release during the subsequent winter. Moreover, trout recaptured in wood-treated sections of the side channels had grown more than trout recaptured in control sections. Wood enrichment in the side channels also increased overwinter site fidelity. These results show that adding structure during a relatively short period may alter growth trajectories, and adding wood to side channels is a cost-effective method to enhance winter habitat carrying capacity for juvenile salmonids in regulated rivers.
  •  
4.
  • Carlsson, Axel C, et al. (författare)
  • 10-Year Associations between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients with Stable Coronary Heart Disease : A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) Trial Substudy.
  • 2018
  • Ingår i: Journal of the American Heart Association. - 2047-9980 .- 2047-9980. ; 7:9
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: We aimed to assess the associations and predictive powers between the soluble receptors for tumor necrosis factor (TNF)-α (TNFR1 and TNFR2) and cardiovascular outcomes in patients with stable coronary heart disease.METHODS AND RESULTS: CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) is a randomized clinical trial comparing clarithromycin with placebo in patients with stable coronary heart disease. The primary outcome was a composite of nonfatal acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, and all-cause mortality. Patients were followed up for 10 years; discovery sample, those assigned placebo (1204 events in n=1998); and replication sample, those assigned clarithromycin (1220 events in n=1979). We used Cox regression adjusted for C-reactive protein level, established cardiovascular risk factors, kidney function, and cardiovascular drugs. After adjustments, higher serum levels of TNFR1 and TNFR2 were associated with the composite outcome in the discovery sample (hazard ratio per SD increase, 1.13; 95% confidence interval, 1.05-1.22; P=0.001 for TNFR1; hazard ratio, 1.16; 95% confidence interval, 1.08-1.24; P<0.001 for TNFR2). The associations were similar in the replication sample. The associations with the composite outcome were mainly driven by acute myocardial infarction, cardiovascular mortality, and noncardiovascular mortality. The addition of TNFR1 and TNFR2 to established cardiovascular risk factors improved prediction only modestly (<1%).CONCLUSIONS: Increased concentrations of circulating TNFR1 and TNFR2 were associated with increased risks of cardiovascular events and mortality in patients with stable coronary heart disease. Yet, the utility of measuring TNFR1 and TNFR2 to improve risk prediction in these patients appears limited.CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00121550.
  •  
5.
  • Carlsson, Jörgen, et al. (författare)
  • EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides
  • 2015
  • Ingår i: Radiology and Oncology. - 1318-2099 .- 1581-3207. ; 49:1, s. 50-58
  • Tidskriftsartikel (refereegranskat)abstract
    • Background. There is limited effect of tyrosine kinase inhibitors or "naked" antibodies binding EGFR or HER2 for therapy of metastasized urinary bladder canter and these methods are therefore not routinely used. Targeting radionuclides to the extracellular domain of the receptors is potentially a better possibility. Methods. EGFR- and HER2-expression was analyzed for primary tumors and corresponding metastases from 72 patients using immunohistochemistry and the internationally recommended HercepTest. Intracellular mutations were not analyzed since only the receptors were considered as targets and intracellular abnormalities should have minor effect on radiation dose. Results. EGFR was positive in 71% of the primary tumors and 69% of corresponding metastases. Local and distant metastases were EGFR-positive in 75% and 66% of the cases, respectively. The expression frequency of HER2 in related lesions was slightly higher (data from previous study). The EGFR-positive tumors expressed EGFR in metastases in 86% of the cases. The co-expression of EGFR and HER2 was 57% for tumors and 53% for metastases. Only 3% and 10% of the lesions were negative for both receptors in tumors and metastases, respectively. Thus, targeting these receptors with radionuclides might be applied for most patients. Conclusions. At least one of the EGFR- or HER2-receptors was present in most cases and co-expressed in more than half the cases. It is therefore interesting to deliver radionuclides for whole-body receptor-analysis, dosimetry and therapy. This can hopefully compensate for resistance to other therapies and more patients can hopefully be treated with curative instead of palliative intention.
  •  
6.
  •  
7.
  • Friedman, Mikaela, et al. (författare)
  • Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule
  • 2009
  • Ingår i: Biotechnology and applied biochemistry. - 0885-4513 .- 1470-8744. ; 54, s. 121-131
  • Tidskriftsartikel (refereegranskat)abstract
    • HER2 (human epidermal-growth-factor receptor-2; ErbB2) and EGFR (epidermal-growth-factor receptor) are overexpressed in various forms of cancer, and the co-expression of both HER2 and EGFR has been reported in a number of studies. The simultaneous targeting of HER2 and EGFR has been discussed as a strategy with which to potentially increase efficiency and selectivity in molecular imaging and therapy of certain cancers. In an effort to generate a molecule capable of bispecifically targeting HER2 and EGFR, a gene fragment encoding a bivalent HER2-binding affibody molecule was genetically fused in-frame with a bivalent EGFR-binding affibody molecule via a (G(4)S)(3) [(Gly(4)-Ser)(3)]-encoding gene fragment. The encoded 30 kDa affibody construct (Z(HER2))(2)-(G(4)S)(3)-(Z(EGFR))(2), with potential for bs (bispecific) binding to HER2 and EGFR, was expressed in Escherichia coli and characterized in terms of its binding capabilities. The retained ability to bind HER2 and EGFR separately was demonstrated using both biosensor technology and flow-cytometric analysis, the latter using HER2- and EGFR-overexpressing cells. Furthermore, simultaneous binding to HER2 and EGFR was demonstrated in: (i) a sandwich format employing real-time biospecific interaction analysis where the bs affibody molecule bound immobilized EGFR and soluble HER2; (ii) immunofluorescence microscopy, where the bs affibody molecule bound EGFR-overexpressing cells and soluble HER2; and (iii) a cell-cell interaction analysis where the bs affibody molecule bound HER2-overexpressing SKBR-3 cells and EGFR-overexpressing A-431 cells. This is, to our knowledge, the first reported bs affinity protein with potential ability for the simultaneous targeting of HER2 and EGFR. The potential future use of this and similar constructs, capable of bs targeting of receptors to increase the efficacy and selectivity in imaging and therapy, is discussed.
  •  
8.
  • Löfblom, John, et al. (författare)
  • Affibody molecules : Engineered proteins for therapeutic, diagnostic and biotechnological applications
  • 2010
  • Ingår i: FEBS Letters. - 0014-5793 .- 1873-3468. ; 584:12, s. 2670-2680
  • Forskningsöversikt (refereegranskat)abstract
    • Affibody molecules are a class of engineered affinity proteins with proven potential for therapeutic, diagnostic and biotechnological applications. Affibody molecules are small (6.5 kDa) single domain proteins that can be isolated for high affinity and specificity to any given protein target. Fifteen years after its discovery, the Affibody technology is gaining use in many groups as a tool for creating molecular specificity wherever a small, engineering compatible tool is warranted. Here we summarize recent results using this technology, propose an Affibody nomenclature and give an overview of different HER2-specific Affibody molecules. Cumulative evidence suggests that the three helical scaffold domain used as basis for these molecules is highly suited to create a molecular affinity handle for vastly different applications.
  •  
9.
  •  
10.
  • Nordberg, Erika, et al. (författare)
  • Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule
  • 2007
  • Ingår i: Nuclear Medicine and Biology. - 0969-8051 .- 1872-9614. ; 34:6, s. 609-618
  • Tidskriftsartikel (refereegranskat)abstract
    • INTRODUCTION: The cellular binding and processing of an epidermal growth factor receptor (EGFR) targeting affibody molecule, (Z(EGFR:955))(2), was studied. This new and small molecule is aimed for applications in nuclear medicine. The natural ligand epidermal growth factor (EGF) and the antibody cetuximab were studied for comparison. METHODS: All experiments were made with cultured A431 squamous carcinoma cells. Receptor specificity, binding time patterns, retention and preliminary receptor binding site localization studies were all made after (125)I labeling. Internalization was studied using Oregon Green 488, Alexa Fluor 488 and CypHer5E markers. RESULTS: [(125)I](Z(EGFR:955))(2) and [(125)I]cetuximab gave a maximum cellular uptake of (125)I within 4 to 8 h of incubation, while [(125)I]EGF gave a maximum uptake already after 2 h. The retention studies showed that the cell-associated fraction of (125)I after 48 h of incubation was approximately 20% when delivered as [(125)I](Z(EGFR:955))(2) and approximately 25% when delivered as [(125)I]cetuximab. [(125)I]EGF-mediated delivery gave a faster (125)I release, where almost all cell-associated radioactivity had disappeared within 24 h. All three substances were internalized as demonstrated with confocal microscopy. Competitive binding studies showed that both EGF and cetuximab inhibited binding of (Z(EGFR:955))(2) and indicated that the three substances competed for an overlapping binding site. CONCLUSION: The results gave information on cellular processing of radionuclides when delivered with (Z(EGFR:955))(2) in comparison to delivery with EGF and cetuximab. Competition assays suggested that [(125)I](Z(EGFR:955))(2) bind to Domain III of EGFR. The affibody molecule (Z(EGFR:955))(2) can be a candidate for EGFR imaging applications in nuclear medicine.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (138)
konferensbidrag (19)
doktorsavhandling (16)
bokkapitel (12)
recension (12)
rapport (11)
visa fler...
annan publikation (9)
bok (6)
forskningsöversikt (2)
licentiatavhandling (1)
patent (1)
visa färre...
Typ av innehåll
refereegranskat (132)
övrigt vetenskapligt (76)
populärvet., debatt m.m. (19)
Författare/redaktör
Carlsson, Jörgen (164)
Tolmachev, Vladimir (66)
Lundqvist, Hans (42)
Gedda, Lars (33)
Orlova, Anna (28)
Sandell, Niklas (17)
visa fler...
Sjöberg, Stefan (16)
Stenerlöw, Bo (15)
Carlsson, J (15)
Sundin, Anders (14)
Blomquist, Erik (14)
Glimelius, Bengt (12)
Ståhl, Stefan (12)
Steffen, Ann-Charlot ... (12)
Sörensen, Jens (10)
Lubberink, Mark (10)
Lindman, Henrik (10)
Lundälv, Jörgen, 196 ... (9)
Sandström, Mattias (9)
Wennborg, Anders (9)
Carlsson, Anna (9)
Feldwisch, Joachim (8)
Malmström, Per-Uno (8)
Wester, Kenneth (8)
Haraldsson, Mattias (8)
Velikyan, Irina (8)
Edwards, Katarina (7)
Lennartsson, Johan (7)
Hoglund, Erik (7)
Glimelius, B (6)
Nordgren, Hans (6)
Carlsson, Jörgen, 19 ... (6)
Persson, Mikael (5)
Sjöberg, S (5)
Tolmachev, V. (4)
Persson, M (4)
Bengtsson, Jörgen, 1 ... (4)
Haglund, Åsa, 1976 (4)
Stahl, S (4)
Nordberg, E. (4)
Feldwisch, J (4)
Frejd, Fredrik Y. (4)
Sjöström, Anna (4)
Carlsson, Axel C. (4)
Wikman, Maria (4)
Gustavsson, Johan, 1 ... (4)
Carlsson, Sten (4)
de la Torre, Manuel (4)
Kilbrink, Nina (4)
Segolsson, Mikael (4)
visa färre...
Lärosäte
Uppsala universitet (145)
Lunds universitet (34)
Göteborgs universitet (14)
Kungliga Tekniska Högskolan (14)
Karolinska Institutet (10)
Umeå universitet (8)
visa fler...
Linköpings universitet (6)
Karlstads universitet (6)
Chalmers tekniska högskola (5)
Högskolan Dalarna (3)
Jönköping University (2)
Stockholms universitet (1)
Örebro universitet (1)
Malmö universitet (1)
Mittuniversitetet (1)
Södertörns högskola (1)
Högskolan i Halmstad (1)
Högskolan i Gävle (1)
VTI - Statens väg- och transportforskningsinstitut (1)
visa färre...
Språk
Engelska (187)
Svenska (38)
Odefinierat språk (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (49)
Samhällsvetenskap (24)
Naturvetenskap (23)
Teknik (21)
Lantbruksvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy